PURPOSE: Locoregional recurrence remains the main pattern of failure after primary combined modality treatment of @entity213 ( @entity213 ). We compared the efficacy and @entity137 of either @entity900 or cetuximab in combination with re-irradiation (ReRT) for recurrent unresectable @entity213 . Various clinicopathological factors were investigated to establish a prognostic score. @entity1 AND METHODS: Between 2007 and 2014, 66 @entity1 with recurrent @entity213 originating in a previously irradiated area received cetuximab (n = 33) or @entity900 -based chemotherapy (n = 33) concomitant with ReRT. @entity137 was evaluated weekly and at every follow-up visit. Physical examination, endoscopy, CT or MRI scans were used to evaluate response and disease control. RESULTS: With a mean follow-up of 18.3 months, the 1-year @entity1349 ( @entity1349 ) rates for Re- @entity138 with cetuximab and @entity900 -based chemotherapy were 44.4 and 45.5% (p = 0.352), respectively. At 1 year, local control rates (LCR) were 46.4 and 54.2% (p = 0.625), freedom from metastases (FFM) rates 73.6 and 81% (p = 0.842), respectively. @entity137 >=  grade 3 occurred more often in the @entity900 group (p < 0.001), @entity158 >=  grade 3 was increased in the cetuximab group (p = 0.034). A physiological haemoglobin level and a longer interval between primary @entity138 and ReRT, proved to be significant prognostic factors for @entity1349 (multivariate: p = 0.003, p = 0.002, respectively). Site of the recurrence and gross target volume (GTV) did not show a significant impact on @entity1349 in multivariate analysis (p = 0.160, p = 0.167, respectively). A prognostic-score (1-4 points) based on these four variables identified significantly different subgroups: 1-year @entity1349 for 0/1/2/3/4 prognostic points: 10, 38, 76, 80 and 100%, respectively (p < 0.001). CONCLUSION: Both cetuximab- and @entity900 -based ReRT of @entity213 recurrences are feasible and effective treatment options with comparable results in @entity5 control and survival. Acute adverse events may differ slightly. Our prognostic score could help to identify appropriate @entity1 for ReRT and stratify @entity1 within future clinical trials.

Re-irradiation with cetuximab or XXXX -based chemotherapy for recurrent @entity213 .

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'Toxicity', 'Haematological toxicity'] @entity138 :: ('MESH:C563738', 'Disease') :: ['RT'] @entity213 :: ('MESH:C535575', 'Disease') :: ['squamous cell carcinoma of the head and neck', 'SCCHN'] @entity5 :: ('MESH:D009369', 'Disease') :: ['terms of tumour'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity900 :: (MESH:D002945,Chemical) :: ['cisplatin']
